![]() ![]() I have major issues with the way the book is written. The investor community largely doesn't understand the sector and hence private funding has been difficult to come by for the sector as a whole, especially from domestic funds. The Indian pharmaceutical industry doesn't have the gumption and in many cases resources to do the hard work and make expensive bets and a non-supportive (almost adversarial) eco-system of regulations, skill-sets and funding makes things harder. However, the government and regulators haven't kept pace with the fast evolving industry landscape and India risks missing out on the biotech boom altogether as biologics replace traditional chemistry based medicines around the world. Serendipity has had no small role to play in the success story though, especially when it was a fledgling outfit. ![]() Without her guts, determination, business acumen and the big risks taken at various points in the company's history, Biocon wouldn't be where it is today. She has genuinely made an effort to develop and support innovation research in India and encourage ex-employees to start something original while putting her money where her mouth is. ![]() However, her career has been more than about just building a successful company. She was the pioneer in the field in India and Biocon continues to be the market leader. The book by Seema Singh (who also writes on healthcare for The Ken) is a great effort to narrate the story of biotech in India with Kiran Mazumdar-Shaw and Biocon as the fulcrum. ![]()
0 Comments
Leave a Reply. |